13 June 2024
BSF Enterprise
PLC
("BSF" or
the "Company")
Grant of
Options
BSF (LSE: BSFA), (OTCQB: BSFAF), a UK
listed biotech company and owner of pioneering UK-based tissue
engineering company, 3D Bio-Tissues (3DBT), and corneal replacement
company, Kerato, announces a grant of
Enterprise Management Incentive options ("Options") over new
ordinary shares at an exercise price of 15 pence each in the
Company ("Ordinary Shares").
Options have been granted in respect
of a total of 2,400,000 new Ordinary Shares to employees of BSF and
its subsidiaries. These new Options represent, in aggregate, 2.23
per cent of the Company's current issued share capital.
The Options are exercisable at 15
pence per Ordinary Share. Of these Options, 1,650,000 will vest on
the 2nd anniversary of the date of grant and 750,000 options
will vest on the 3rd anniversary of the date of grant.
An Option may be exercised from the
third anniversary of the Date of Grant. An Option shall not be
exercisable more than ten years after the Date of Grant.
Following the Options grant, the
Company will have a total of 2,400,000 options over Ordinary Shares
in issue.
For
further enquiries, please visit www.bsfenterprise.com or
contact:
|
BSF
Enterprise PLC
|
Via SEC Newgate below
|
|
Geoff Baker - Executive
Director
Che Connon - CEO &
Director
|
|
|
|
|
|
Shard Capital (Broker)
|
|
|
Damon Heath
Isabella Pierre
|
0207 186 9000
0207 186 9927
|
|
|
|
|
SEC
Newgate (Financial Communications)
|
|
|
|
|
|
Bob Huxford
Elisabeth Cowell
George Esmond
|
020 3757 6882
BSF@secnewgate.co.uk
|
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
Notes to Editors
BSF Enterprise PLC (BSF) is focused
on unlocking the next generation of biotechnological solutions to
deliver sustainable materials and products across
a variety of sectors. BSF Enterprise's core technology
platform in industrial tissue engineering allows the manufacture at
scale of lab-grown alternatives to animal and human tissues,
helping deliver sustainable products and materials of the future.
The Company's technologies have multiple applications across
consumer and medical markets including lab-grown leather,
cultivated meat, human corneas and in vitro animal
models.
BSF owns 100% of pioneering UK-based
tissue engineering companies 3D Bio-Tissues (3DBT), that
successfully produced the UK's first high-quality cultivated meat
and lab-grown skin from its laboratory and Kerato, a developer of
lab-grown corneal replacement tissue for medical and research uses.
In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited
which is actively supporting commercialisation of our technology in
China and Asia.
BSF aims to deliver growth to
shareholders through the continued commercialisation and expansion
of the Groups IP, which has multiple applications, as well as
through M&A. BSF aims to build a comprehensive portfolio in
tissue engineering and related applications and license out IP to
various stakeholders in the supply chain to enable manufacture at
scale and achieve widespread market penetration.